Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerry Taylor

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Blood|October 31, 2002
Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expressionSlavica Vuckovic, Min Kim, Dailal Khalil, et al.
Blood Advances|May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16Peter Mollee, John Reynolds, Wojt Janowski, et al.
Blood|June 21, 2012
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Harry J Iland, Ken Bradstock, Shane G Supple, et al.
The Lancet. Haematology|December 22, 2015
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialHarry J Iland, Marnie Collins, Ken Bradstock, et al.
Blood|June 24, 2004
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabineKenneth F Bradstock, Jane P Matthews, Raymond M Lowenthal, et al.
Blood|September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyTimothy P Hughes, Susan Branford, Deborah L White, et al.
The Journal of Rheumatology|March 3, 2004
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTRJohn A Snowden, Jakob Passweg, John J Moore, et al.
The New England Journal of Medicine|March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, François Guilhot, Richard A Larson, et al.
Blood Advances|September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final dataSteven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
Lancet (London, England)|June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH Miles Prince, Youn H Kim, Steven M Horwitz, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Blood|October 31, 2002
Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expressionSlavica Vuckovic, Min Kim, Dailal Khalil, et al.
Blood Advances|May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16Peter Mollee, John Reynolds, Wojt Janowski, et al.
Blood|June 21, 2012
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Harry J Iland, Ken Bradstock, Shane G Supple, et al.
The Lancet. Haematology|December 22, 2015
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialHarry J Iland, Marnie Collins, Ken Bradstock, et al.
Blood|June 24, 2004
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabineKenneth F Bradstock, Jane P Matthews, Raymond M Lowenthal, et al.
Blood|September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyTimothy P Hughes, Susan Branford, Deborah L White, et al.
The Journal of Rheumatology|March 3, 2004
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTRJohn A Snowden, Jakob Passweg, John J Moore, et al.
The New England Journal of Medicine|March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, François Guilhot, Richard A Larson, et al.
Blood Advances|September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final dataSteven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
Lancet (London, England)|June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH Miles Prince, Youn H Kim, Steven M Horwitz, et al.
Pageof 7